Physician profile
John Depaula
NPI 1356447635
$16,981.53
in general payments reported to CMS, 2019-2025
35 companies · $2,476 in 2025
The $2,476 reported for 2025 was more than what 87% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,135 · 2020: $2,050 · 2021: $2,558 · 2022: $2,399 · 2023: $2,650 · 2024: $2,713 · 2025: $2,476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,476 · Education: $363.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,475.50 |
| Education | $363.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $4,095.42 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Gilead Sciences, INC. | $2,101.85 | 2019-2025 | Veklury, Biktarvy |
| Paratek Pharmaceuticals, INC. | $1,833.23 | 2019-2025 | Nuzyra |
| Merck Sharp & Dohme LLC | $1,236.17 | 2019-2025 | Pifeltro, Dificid, Delstrigo |
| Insmed, INC. | $1,100.81 | 2019-2025 | Arikayce |
| Abbvie INC. | $1,063.23 | 2021-2025 | Avycaz, Teflaro, Dalvance |
| Janssen Biotech, INC. | $978.67 | 2019-2023 | Symtuza |
| Theratechnologies INC. | $752.19 | 2019-2025 | Egrifta, Trogarzo |
| Melinta Therapeutics, LLC | $632.89 | 2019-2025 | Rezzayo, Kimyrsa, Orbactiv |
| Astellas Pharma US INC | $605.20 | 2019-2025 | Cresemba |
| Emd Serono, INC. | $474.23 | 2019-2024 | Serostim |
| Shionogi INC | $282.92 | 2021-2025 | Fetroja |
| Napo Pharmaceuticals INC | $275.99 | 2019-2024 | Mytesi |
| Pfizer INC. | $211.42 | 2022-2025 | |
| Allergan, INC. | $201.37 | 2019-2020 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $199.76 | 2020-2022 | |
| Ferring Pharmaceuticals INC. | $112.97 | 2023-2025 | Rebyota |
| Accelerate Diagnostics INC. | $86.96 | 2020 | |
| La Jolla Pharmaceutical Company | $79.15 | 2024-2025 | Xacduro, Zevtera |
| Qiagen, LLC | $75.23 | 2019 | |
| Smith+Nephew, INC. | $73.61 | 2023-2024 | Collagenase Santyl, Iodosorb Ointment 40g USA, Regranex |
| Mayne Pharma Commercial LLC | $67.29 | 2019-2022 | |
| Invivyd INC | $59.42 | 2024-2025 | Pemgarda |
| Kowa Pharmaceuticals America, INC. | $50.12 | 2021-2024 | Livalo |
| Organogenesis INC. | $47.91 | 2023 | Puraply |
| Tetraphase Pharmaceuticals, INC. | $45.97 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $42.48 | 2019-2021 | |
| Tactile Systems Technology INC | $34.87 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $33.99 | 2021-2023 | |
| Janssen Products, Lp | $29.99 | 2019 | |
| Vyera Pharmaceuticals, LLC | $25.38 | 2020 | |
| Nabriva Therapeutics, Plc | $23.32 | 2020-2021 | |
| Hologic Sales and Service, LLC | $17.18 | 2021 | |
| Pharming Healthcare, INC. | $15.22 | 2024 | Ruconest |
| Philips North America LLC | $15.12 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Depaula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.